Stay updated with breaking news from Jesus berdeja. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jesus Berdeja, MD, discussed considerations when choosing between bispecific antibodies and CAR T-cell therapy for patients with multiple myeloma, clinical trials that may move CAR T-cell therapy into earlier lines, and research with agents directed at targets other than BCMA. ....
Jesus Berdeja, MD, discusses factors to consider when choosing between CAR T-cell therapy and bispecific antibodies in patients with multiple myeloma. ....
/PRNewswire/ K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing novel targeted therapies for the unmet medical needs of. ....